Development of a novel six-long non-coding RNA signature predicting survival of patients with bladder urothelial carcinoma

Bladder urothelial carcinoma is a
malignant tumor with a high incidence in the uropoietic system. Considerable studies have shown that
long non-coding RNA (lncRNA) plays an important role in the development and
progression of bladder urothelial carcinoma. In this study, the lncRNA expression and clinical data
of 377 bladder urothelial carcinoma patients were obtained from The Cancer
Genome Atlas (TCGA) database,
and differentially expressed lncRNAs in the cancer and normal groups were
evaluated.
Univariate COX and
multivariate COX regression analyses of prognosis were performed on
differentially expressed lncRNAs in the training datasets, six prognosis-related
lncRNAs (LINC02195, LINC01484, LINC01468, SMC2-AS1, AC011298.1, and PTPRD-AS1)
were assessed, and a 6-lncRNA signature was constructed. The predictive capability of this 6-lncRNA
signature was validated in the testing datasets and entire datasets. The prognostic
ability of 6-lncRNA signature was independent of other clinical elements after multivariate
COX regression and stratified analyses of with other clinical elements. We
performed functional enrichment analysis with the six prognosis-related lncRNAs.
Results of functional enrichment revealed that these prognosis-related lncRNAs
might promote the development and metastasis of bladder urothelial carcinoma. In
summary, the 6-lncRNA signature that we developed could effectively predict the
prognosis of bladder urothelial carcinoma patients. This 6-lncRNA signature might
be a novel independent prognostic marker of bladder urothelial carcinoma. Moreover，it also provides novel insights into the
mechanism of bladder urothelial carcinoma.